Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mabwell’s Denosumab Biosimilar Shows Similar Efficacy To Xgeva

The Phase III Trial Enrolled Solid Tumor Patients With Bone Metastasis

Executive Summary

Mabwell’s denosumab biosimilar MW032, which awaits approval in China, achieved similar efficacy and safety profiles as the originator Xgeva in oncology patients.

You may also be interested in...



Sandoz Gets US Denosumab Approvals – But When Will They Launch?

Sandoz has received the first FDA approvals for denosumab biosimilar rivals to Prolia and Xgeva under the names Wyost and Jubbonti. However, the firm has declined to comment on launch details while it remains locked in litigation with originator Amgen.

Mabwell To Roll Out Denosumab Biosimilars Across Pakistan And Egypt

Chinese biopharma Mabwell has formed licensing agreements in Pakistan and Egypt to roll out its denosumab biosimilars.

Russia’s Binnopharm Brings In Mabwell’s Adalimumab, Denosumab Biosimilars

China’s Mabwell has furthered its strategy to bring its biosimilars to global markets “for the benefit of millions of patients around the world” via a licensing agreement with Russian player Binnopharm.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel